(UroToday.com) As part of a plenary presentation at the European Urologic Association Virtual Annual Meeting assessing “Modern prostate cancer imaging in daily practice,” Dr. Boris Hadaschik examined the question of prostate cancer risk stratification on the basis of targeted biopsies. As most will know, the commonly utilized nomograms were derived on the basis of standard, systematic TRUS prostate biopsy. How to utilize targeted biopsy data is somewhat uncertain.